Science Explorer Back to mapMap
Discussion
Researcher · Hellenic Oncology Research Group · Greece

Nikolaos Kentepozidis

Nikolaos Kentepozidis publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Cancer Research, on topics such as Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology and Colorectal Cancer Treatments and Studies.

ORCID 0000-0002-6037-5707 OpenAlex
World rank
#4,898,333
of 7,710,434 ranked researchers
Rank in Greece
#22,845
of 33,280
Works
93
Citations
1.4k
Citations per work
14.9
h-index
22
i10-index 43Top 20% in Oncology
Nikolaos Kentepozidis

What does Nikolaos Kentepozidis research?

Nikolaos Kentepozidis's work is mostly in Medicine (73%), Biochemistry, Genetics and Molecular Biology (13%).

Health Sciences: 68 works · 73.2% of their workMedicine: 68 works · 73.2% of their workOncology: 39 works · 41.4% of their workPulmonary and Respiratory Medicine: 24 works · 25.3% of their workSurgery: 3 works · 3.4% of their workPathology and Forensic Medicine: 3 works · 3.1% of their workEverything else: 13 works · 13.8% of their workLife Sciences: 12 works · 13.0% of their workBiochemistry, Genetics and Molecular Biology: 12 works · 13.0% of their workCancer Research: 7 works · 8.0% of their workMolecular Biology: 5 works · 5.0% of their workTHEIR WORKNikolaosKentepozidis93works
Life Sciences13%Health Sciences73%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine6873.2%
  2. Everything else1313.8%
    1. Biochemistry, Genetics and Molecular Biology1213.0%
  1. 1Oncology41% of their works
  2. 2Pulmonary and Respiratory Medicine25% of their works
  3. 3Cancer Research8% of their works
  4. 4Molecular Biology5% of their works
  5. 5Surgery3% of their works
  6. 6Pathology and Forensic Medicine3% of their works

Research topics

Which keywords describe Nikolaos Kentepozidis's research?

The keywords of their largest research topics: Chemotherapy, Clinical Trials, Targeted Therapy, ALK Inhibitors, EGFR Mutations, Molecular Subtypes, Chemotherapy-Induced Peripheral Neuropathy and Taxanes.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.

All 24 words, with their numbers
  1. Chemotherapy614 topics
  2. Clinical Trials522 topics
  3. Targeted Therapy522 topics
  4. ALK Inhibitors331 topic
  5. EGFR Mutations331 topic
  6. Molecular Subtypes332 topics
  7. Chemotherapy-Induced Peripheral Neuropathy301 topic
  8. Taxanes301 topic
  9. Radiotherapy292 topics
  10. Immunotherapy272 topics
  11. Neoadjuvant Therapy222 topics
  12. Cetuximab191 topic
  13. Genomic Profiles191 topic
  14. KRAS Mutations191 topic
  15. Small-Cell Lung Cancer191 topic
  16. CT Screening151 topic
  17. Lung Cancer151 topic
  18. Tumor Microenvironment152 topics
  19. Breast Tumours141 topic
  20. Gene Expression141 topic
  21. Pancreatic Cancer81 topic
  22. Surgical Complications81 topic
  23. Immune Checkpoint Blockade71 topic
  24. PD-1 and PD-L171 topic

Where does Nikolaos Kentepozidis work?

Nikolaos Kentepozidis's main affiliation in the publication record is Hellenic Oncology Research Group, Greece.

How many publications and citations does Nikolaos Kentepozidis have?

OpenAlex counts 93 works and 1,387 citations for Nikolaos Kentepozidis, an h-index of 22, ranking #4,898,333 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Nikolaos Kentepozidis. Posts are plain text and can be reported.